. 2022 May 14:2022:7306198.

doi: 10.1155/2022/7306198. eCollection 2022.

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Junlan Qiu¹, Haifeng Zhang², Dongkui Xu³, Lin Li², Lingkai Xu⁴, Yiqing Jiang⁵, Tao Wen⁶, Shun Lu⁷, Fang Meng^{8

9}, Lin Feng¹, Xiaochen Shu^{2

10}

Affiliations

¹ Department of Oncology and Hematology, The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou 215153, China.
² Department of Epidemiology, School of Public Health, Soochow University, Suzhou 215123, China.
³ VIP Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
⁴ Department for Communicable Disease Control and Prevention, Suzhou Wuzhong Center for Disease Prevention and Control, Suzhou 215128, China.
⁵ Department of General Surgery, Harrison International Peace Hospital, Hengshui 053000, China.
⁶ Medical Research Centre, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
⁷ Department of Radiation Oncology, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, 610041 Chengdu, China.
⁸ Centre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁹ Suzhou Institute of Systems Medicine, Suzhou 215123, China.
¹⁰ Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou 215123, China.

PMID: 35607328
PMCID: PMC9124076
DOI: 10.1155/2022/7306198

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Junlan Qiu et al. J Oncol. 2022.

. 2022 May 14:2022:7306198.

doi: 10.1155/2022/7306198. eCollection 2022.

Authors

Junlan Qiu¹, Haifeng Zhang², Dongkui Xu³, Lin Li², Lingkai Xu⁴, Yiqing Jiang⁵, Tao Wen⁶, Shun Lu⁷, Fang Meng^{8

9}, Lin Feng¹, Xiaochen Shu^{2

10}

Affiliations

¹ Department of Oncology and Hematology, The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou 215153, China.
² Department of Epidemiology, School of Public Health, Soochow University, Suzhou 215123, China.
³ VIP Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
⁴ Department for Communicable Disease Control and Prevention, Suzhou Wuzhong Center for Disease Prevention and Control, Suzhou 215128, China.
⁵ Department of General Surgery, Harrison International Peace Hospital, Hengshui 053000, China.
⁶ Medical Research Centre, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
⁷ Department of Radiation Oncology, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, 610041 Chengdu, China.
⁸ Centre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁹ Suzhou Institute of Systems Medicine, Suzhou 215123, China.
¹⁰ Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou 215123, China.

PMID: 35607328
PMCID: PMC9124076
DOI: 10.1155/2022/7306198

Abstract

Background: Although radical cystectomy (RC) is the clinical practice guideline-recommended treatment of muscle-invasive bladder cancer (MIBC), bladder-sparing trimodality therapy (TMT) has emerged as a valid treatment option. Findings comparing the survival outcomes for MIBC patients who underwent RC and TMT are inconclusive.

Objective: We designed a large hospital-based multicohort study to compare the effectiveness of TMT with RC.

Methods: Information on deaths was jointly retrieved from EMR (electronic medical record), cause of death registry, and chronic disease surveillance as well as study-specific questionnaire. To avoid the systematical difference between patients who received two modalities, RC-MIBC cohort was propensity score-matched to TMT-MIBC cohort, and the Cox proportional hazard regression was used to calculate the overall survival (OS) and disease-specific survival (DSS).

Results: There were 891 MIBC patients treated with RC and another 891 MIBC patients who underwent with TMT in the propensity score matching. Comparable effectiveness between two modalities was observed for DSS (HR, 1.20; 95% confidence interval (CI), 0.94 to 1.49) and OS (HR, 1.17; 95% CI, 0.91 to 1.43) according to multiple adjustment after a median follow-up of approximately 9.3 years. However, a relatively higher mortality rate around 5 years after TMT treatment was found compared to RC (HR, 1.26; 95% CI, 1.01 to 1.53). The respective 5-year OS rates were 69% and 73% for TMT cohort and RC cohort, respectively.

Conclusions: Our findings supported that MIBC patients with TMT yielded survival outcomes comparable to MIBC patients who underwent RC overall. Treatment options should be suggested considering patients' age and willingness.

PubMed Disclaimer

Conflict of interest statement

Authors declared that they had no conflicts of interest.

Figures

**Figure 1**
Flow diagram of study participants.

**Figure 2**
(a) Probability of disease-specific survival (DSS) of MIBC patients who underwent TMT in comparison with MIBC patients treated with RC. (b) Probability of overall survival (OS) of MIBC patients who underwent TMT in comparison with MIBC patients treated with RC.

See this image and copyright information in PMC

Cited by

Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
Su X, Dong C, Liao W, Liu W. Su X, et al. World J Surg Oncol. 2023 Aug 29;21(1):271. doi: 10.1186/s12957-023-03161-z. World J Surg Oncol. 2023. PMID: 37641150 Free PMC article.
Comparative Outcomes of Radical Cystectomy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Waraich TA, Khalid SY, Ali A, Kathia UM. Waraich TA, et al. Cureus. 2023 Dec 17;15(12):e50646. doi: 10.7759/cureus.50646. eCollection 2023 Dec. Cureus. 2023. PMID: 38229790 Free PMC article. Review.
Development and validation of interpretable machine learning models to predict distant metastasis and prognosis of muscle-invasive bladder cancer patients.
Deng Q, Li S, Zhang Y, Jia Y, Yang Y. Deng Q, et al. Sci Rep. 2025 Apr 6;15(1):11795. doi: 10.1038/s41598-025-96089-1. Sci Rep. 2025. PMID: 40189676 Free PMC article.
Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review.
Lemiński A, Michalski W, Masojć B, Kaczmarek K, Małkiewicz B, Kienitz J, Zawisza-Lemińska B, Falco M, Słojewski M. Lemiński A, et al. J Clin Med. 2023 Feb 16;12(4):1560. doi: 10.3390/jcm12041560. J Clin Med. 2023. PMID: 36836093 Free PMC article. Review.
Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?
Marvaso G, Vitullo A, Corrao G, Vincini MG, Zaffaroni M, Villa R, Mastroleo F, Kuncman L, Zerini D, Repetti I, Lorubbio C, Musi G, De Cobelli O, Jereczek-Fossa BA. Marvaso G, et al. Tumori. 2024 Jun;110(3):193-202. doi: 10.1177/03008916241252326. Epub 2024 May 10. Tumori. 2024. PMID: 38726748 Free PMC article.

See all "Cited by" articles

References

1. Sung H., Ferlay J., Siegel R. L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
1. Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. Cancer statistics, 2021. CA: a Cancer Journal for Clinicians . 2021;71(1):7–33. doi: 10.3322/caac.21654. - DOI - PubMed
1. Spiess P. E., Agarwal N., Bangs R., et al. Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network . 2017;15(10):1240–1267. doi: 10.6004/jnccn.2017.0156. - DOI - PubMed
1. Gore J. L., Litwin M. S., Lai J., et al. Use of radical cystectomy for patients with invasive bladder cancer. Journal of the National Cancer Institute . 2010;102(11):802–811. doi: 10.1093/jnci/djq121. - DOI - PMC - PubMed
1. Williams S. B., Shan Y., Jazzar U., et al. Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer. JAMA Surgery . 2018;153(10):881–889. doi: 10.1001/jamasurg.2018.1680. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Affiliations

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources